TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11059698
Drug: Monthly reports
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly reports for monitoring subject enrollment and data integrity checks
Study: 2142949
Drug: Mannitol -
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol - 15% at 100 ml/hr
Study: 301743
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (CABG)
Study: 28371189
Drug: Glucagon stimulation
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon stimulation test (GST) with 1 mg i.v. glucagon
Study: 11243418
Drug: Almotriptan 25
Normalized name: almotriptan 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 25 mg
Study: 11075844
Drug: Almotriptan 6.25
Normalized name: almotriptan 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 6.25 mg
Study: 11743622
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 1% pilocarpine solution
Study: 16905851
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy
Study: 2686429
Drug: Ceftazidime plus
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime plus amikacin followed by oral ciprofloxacin (regimen 3)
Study: 22929568
Drug: abciximab infusion
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab infusion with the ClearWay coronary catheter (C)
Study: 22929568
Drug: thrombectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thrombectomy followed by standard abciximab infusion (T+A)
Study: 1550080
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion
Study: 1550080
Drug: 5-FU plus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU plus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU on days 2 to 6
Study: 23360692
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of lutein daily
Study: 20727555
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg, vitamin B6 40 mg, and cyanocobalamin 2 mg per day for 3 weeks
Study: 10048518
Drug: Ulnar nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulnar nerve block with mepivacaine HCI injection
Study: 10048518
Drug: Median nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median nerve block with mepivacaine HCI injection
Study: 31397611
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (no treatment)
Study: 1094253
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with conjugated Estrogens (Presomen) and synthetic Gestagen
Study: 23168298
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (25 μg, 1000 IU)
Study: 23168298
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (25 μg, 1000 IU)
Study: 20864814
Drug: JE vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE vaccine
Study: 15650459
Drug: Patient-specific dendritic
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific dendritic cell vaccine with GM-CSF, administered subcutaneously once a week for 3 weeks, then once a month for 5 months.
Study: 16047530
Drug: Depression at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression at treatment entry
Study: 16327334
Drug: Efavirenz 800
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 800 mg/day
Study: 7681050
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose rate brachytherapy (1000 cGy at 5 mm depth for three fractions)
Study: 1607678
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil
Study: 3900155
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical minoxidil
Study: 19507081
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of red wine (0.4 ml ethanol per kg per day for 7.5 days)
Study: 27182031
Drug: IDeg flexible
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg flexible dosing
Study: 22404081
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment using removable partial dentures
Study: 8722350
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration on day 6 after transplantation (group 2)
Study: 18706557
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral hormone therapy (E(2) 1 mg plus drospirenone 2 mg/d for 2 months)
Study: 18706557
Drug: Nonoral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonoral hormone therapy (3 mg/d 17beta intranasal E(2) and 200 mg/d vaginal micronized P for 14 days during two 28-day cycles)
Study: 16461091
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil 45 minutes before coitus plus topical EMLA cream applied 15 minutes before coitus for 2 months (Group 3)
Study: 16461091
Drug: Topical EMLA-cream-only
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EMLA-cream-only for 2 months (Group 4)
Study: 6119780
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg t.d.s. and 400 mg at night
Study: 18807128
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg
Study: 17533782
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine ophthalmic emulsion
Study: 12358335
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (BDP)
Study: 2839444
Drug: Post-operative thoracic
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative thoracic radiation with systemic chemotherapy (cytoxan, adriamycin, and platinum) for 6 months
Study: 15164445
Drug: Cytoreduction followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 12583553
Drug: clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500 mg + amikacin 250 mg i.v. b.i.d.
Study: 20108648
Drug: 333 mg
Normalized name: aspirin 333 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 333 mg acamprosate calcium
Study: 20108648
Drug: 666 mg
Normalized name: lactulose 666 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 666 mg acamprosate calcium
Study: 7611579
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion to reduce mean arterial blood pressure to 50 mmHg
Study: 11932266
Drug: Dihydrotestosterone (DHT)
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT) gel, administered transdermally for 6 months, dosage varied from 125-250 mg/d
Study: 28317660
Drug: Intradermal with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal with DebioJect™ (IDJ)
Study: 16478005
Drug: amoxicillin capsule
Normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin capsule (reference)
Study: 11136838
Drug: ABMT arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABMT arm (high-dose chemotherapy plus autologous bone marrow transplantation)
Study: 24659740
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (standard chemotherapy)
Study: 30903410
Drug: Bone allograft
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone allograft with gentamicin (8 mg gentamicin/gram bone solution for 1 hour)
Study: 10432132
Drug: Transdermal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal progesterone cream
Study: 19294776
Drug: Pharmaceutical-grade heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical-grade heroin under medical supervision
Study: 11783226
Drug: Composite Xiansu
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite Xiansu Capsule (CXSC) combined with chemotherapy
Study: 7974373
Drug: CRVO patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRVO patients with Lp(a) > 300 mg/l
Study: 1157027
Drug: Postoperative irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative irradiation therapy
Study: 17694218
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of 1% ropivacaine gel (ropivacaine‐60)
Study: 17694218
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of benzocaine gel (benzocaine‐20)
Study: 15990633
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine supplementation (0.3 g/kg per day)
Study: 1394916
Drug: mebendazole composite
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mebendazole composite (mebendazole 100 mg and levamisole 25mg bid x 3d)
Study: 8477961
Drug: Oxandrolone with
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone with enteral food supplement
Study: 18056490
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (20 mL of 0.5% bupivacaine) along with standard pain management
Study: 1353088
Drug: Topical antiseptics
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiseptics (alcohol wipes and hexachlorophane powder)
Study: 12571845
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 40 mg
Study: 9349933
Drug: Oral 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 6-mercaptopurine (50-165 mg.m-2.day-1)
Study: 1534089
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg monthly combined with oral MPA 15 mg daily for 6 months
Study: 26122686
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy + home exercise program
Study: 20183391
Drug: Clinician-assisted emotional
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-assisted emotional disclosure therapy
Study: 23906815
Drug: Noninvasive mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive mechanical ventilation (NIV) combined with conventional therapy
Study: 29945674
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment from month 4 to month 12 after an observational period.
Study: 12946763
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily for 28 days
Study: 27565717
Drug: SMS reminder
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminder messages (monthly)
Study: 11127759
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens (0.3 mg, 0.625 mg, or 1.25 mg)
Study: 7555975
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) HCl, single doses of 2-24 mg
Study: 7555975
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) HCl, daily doses of 6 or 12 mg for 14 days
Study: 23531117
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norethisterone acetate (NETA)/1.0 mg E2
Study: 28492195
Drug: Triclofos sodium
Normalized name: triclofos sodium
DrugBank: Triclofos (DB06753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclofos sodium (70 mg/kg body weight)
Study: 18820852
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet supplemented with keto-amino acids (100 mg/kg BW per day)
Study: 29140444
Drug: Intramuscular control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular control vaccine (hepatitis A)
Study: 8946434
Drug: d-fenfluramine HCl
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine HCl 0.5 mg/kg
Study: 8946434
Drug: d-fenfluramine HCl
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine HCl 1.0 mg/kg
Study: 10400480
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (2 sprays per nostril bid, 1.1 mg/day)
Study: 1878075
Drug: Alcoholic beverages
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic beverages (40 g alcohol) in the form of beer, red wine, or spirits
Study: 15507864
Drug: Low-dose balsalazide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose balsalazide (2.25 g/day) plus VSL#3 (3 g/day)
Study: 12622761
Drug: Standard budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard budesonide capsules
Study: 8017464
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/day
Study: 10671903
Drug: MDMA 125
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 125 mg
Study: 7707112
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for a 5-year increase in length of survival
Study: 27207626
Drug: Feedback on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback on antihypertensive medications
Study: 11784476
Drug: Ethanol 0
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0 g/kg (placebo)
Study: 8590608
Drug: Ethanol 0.35
Normalized name: ethanol 0.35 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.35 g/kg
Study: 31103123
Drug: Qigong practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong practice (Guan Yin Zi Zai Gong level 1) for one hour per week for six weeks, encouraged to practice daily at home.
Study: 23881309
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavior therapy (iCBT)
Study: 27440192
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week supervised exercise therapy
Study: 7720759
Drug: HCTZ 12.5
Normalized name: HCTZ 12.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 12.5 mg b.i.d. (steady-state)
Study: 3890601
Drug: Fenoterol inhalation
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol inhalation powder
Study: 30521533
Drug: Pregabalin treatment
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin treatment
Study: 28915900
Drug: α-GalCer-pulsed dendritic
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-GalCer-pulsed dendritic cell therapy
Study: 7942668
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with omeprazole 40 mg and amoxicillin
Study: 24945932
Drug: Naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 25 mg single oral dose
Study: 28531910
Drug: No intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intra-arterial treatment (Control)
Study: 8465408
Drug: Albendazole 600
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 600 mg
Study: 11318574
Drug: Mebendazole 600
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 600 mg (2 doses per year)
Study: 11318574
Drug: Mebendazole 600
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 600 mg (3 doses per year)
Study: 3124593
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat intake (450 mg.kg‐1.d‐1) at 80 kcal.kg‐1.d‐1
Study: 24914136
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment (hydroxyurea/phlebotomy)
Study: 30359438
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g lactulose
Study: 17532415
Drug: ET-A receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-A receptor antagonist 2 mg/kg (n = 8)
Study: 21228310
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice daily for 6 months
Study: 26871201
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pregabalin (PGL)
Study: 24062546
Drug: Antenatal magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal magnesium sulfate (MgSO4) - initial dose 4 g, maintained at 1 g/h up to maximum of 24 h
Study: 2203252
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g FO, supplying 2 g n-3 fatty acids
Study: 19196892
Drug: Digoxin therapy
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin therapy
Study: 1627030
Drug: Serum cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum cholesterol level less than 4.14 mmol/L (less than 160 mg/dL)
Study: 26828770
Drug: Group-delivered integrated
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-delivered integrated cognitive behavioral therapy
Study: 24746411
Drug: Pulverized brand-name
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulverized brand-name and generic drugs containing amlodipine (Norvasc(®), Amlodipin‐Mepha(®), Amlodipin Pfizer(®))
Study: 1702582
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy
Study: 12524069
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (50 mg) with ethinyl estradiol (EE)
Study: 6366807
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream 0.1%
Study: 6366807
Drug: Dithranol ointment
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol ointment 0.25%
Study: 7724298
Drug: Glucose-based oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based oral rehydration solution (Pedialyte)
Study: 7724298
Drug: Rice syrup
Normalized name: Rice Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice syrup solids-based ORS (Infalyte)
Study: 18633172
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg
Study: 9005368
Drug: Ipriflavone 600
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone 600 mg/day per os
Study: 9917047
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray, 100 microg/day for 4 to 6 weeks
Study: 27029706
Drug: Trebananib 15
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib 15 mg/kg QW plus weekly paclitaxel